Xoma
Executive Summary
Biotech firm files to register $ 50 mil. in convertible subordinated debentures with the Securities and Exchange Commission. Proceeds are expected to be used to support expansion of manufacturing capacity for Xomen-E5 and XomaZyme-H65, development of a marketing and sales force for XomaZyme-H65 and working capital requirements. Dillon Reed, Alex. Brown and Oppenheimer are the underwriters.